Pfizer's Sutent Expanded Indication: 'Hope' Or 'False Hope'?

 
• By Derrick Gingery
  
FDA Advisory Committee Feature image
Oncologic Drugs Advisory Committee votes 6-6 on whether the risk-benefit profile for Sutent's indication expansion is acceptable.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers